Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 9, 2010, Pages 1153-1161

  Moura, A S ^a,c   Carmo, R A ^b   Teixeira, A L ^a   Leite, V H R ^a   Rocha, M O C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Belo Horizonte City Health Department   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD; CHEMISTRY; CYTOCHEMISTRY; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; MALE; MICROSCOPY; MIDDLE AGED; PATHOLOGY; PLASMA;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MICROSCOPY; MIDDLE AGED; PLASMA; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 78349293059     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-010-0981-4     Document Type: Article

References (66)

1. Brown RS Jr, Gaglio PJ (2003) Scope of worldwide hepatitis C problem. Liver Transpl 9:S10-S13
2. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41-52
3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058
4. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125:1695-1704
5. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832
6. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739
7. Friedman SL (1999) Cytokines and fibrogenesis. Semin Liver Dis 19:129-140
8. Friedman SL (2003) Liver fibrosis - from bench to bedside. J Hepatol 38(Suppl 1):S38-S53
9. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW (1996) Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24:759-765
10. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology 124:97-104
11. Chang KM, Rehermann B, Chisari FV (1997) Immunopathology of hepatitis C. Springer Semin Immunopathol 19:57-68
12. Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Bourliere M, Katz GG, Shear NH, Marcellin P (2002) Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 9:134-140
13. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P (2002) Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 17:108-117
14. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M (1989) Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 10:769-773
15. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z (2007) Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 149:126-136
16. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Bréchot C, Zavala F (1999) Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185-191
17. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 87:3127-3131
18. Hohmann HP, Remy R, Brockhaus M, van Loon AP (1989) Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 264:14927-14934
19. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF (1991) Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 266:18846-18853
20. Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T (1995) Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 25:2714-2717
21. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM (1994) Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24:2699-2705
22. Lantz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2:402-406
23. Tilg H, Vogel W, Dinarello CA (1995) Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 85:433-435
24. Fabris C, Del Forno M, Falleti E, Toniutto P, Pirisi M (1999) Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C. Clin Exp Immunol 117:556-560
25. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 89:4845-4849
26. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445
27. Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675-705
28. Mackay CR (1997) Chemokines: what chemokine is that? Curr Biol 7:R384-R386
29. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:108-115
30. Kunkel SL (1999) Through the looking glass: the diverse in vivo activities of chemokines. J Clin Invest 104:1333-1334
31. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621
32. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M (2003) Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 111:1185-1199
33. Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T (2008) Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 14:7149-7159
34. Moura AS, Carmo RA, Teixeira AL, Rocha MOC (2009) Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C. Braz J Infect Dis 13:375-382
35. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187:129-134
36. Koziel MJ (1999) Cytokines in viral hepatitis. Semin Liver Dis 19:157-169
37. Apolinario Fernández de Sousa A, García Monzón C (2003) Role of chemokines in the pathogenesis of liver diseases. Rev Esp Enferm Dig 95:614-620
38. Rehm J (1998) Measuring quantity, frequency, and volume of drinking. Alcohol Clin Exp Res 22:4S-14S
39. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293
40. Brunt EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24:3-20
41. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3-16
42. Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR (2006) Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol 28:473-478
43. Porteu F, Hieblot C (1994) Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem 269:2834-2840
44. Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, Minami M, Murakami Y, Kashima K (1999) Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 94:1332-1340
45. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H, Yoshioka K, Yoshika Y (1997) Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 109:458-463
46. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S (1998) Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269-277
47. Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90:533-536
48. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D (1995) Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54:1-8
49. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JY (1997) The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158:1473-1481
50. Kountouras J, Zavos C, Chatzopoulos D (2003) Apoptosis in hepatitis C. J Viral Hepat 10:335-342
51. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM (1997) Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 42:2277-2284
52. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH (2008) Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48:1440-1450
53. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH (1999) Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 163:6236-6243
54. Apolinario A, Majano PL, Alvarez-Pérez E, Saez A, Lozano C, Vargas J, García-Monzón C (2002) Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 97:2861-2870
55. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C (2009) Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137:309-319
56. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB (2005) Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106:1175-1182
57. Apolinario A, Diago M, Lo Iacono O, Lorente R, Pérez C, Majano PL, Clemente G, García-Monzón C (2004) Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Aliment Pharmacol Ther 19:551-562
58. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101:746-754
59. Park MK, Amichay D, Love P, Wick E, Liao F, Grinberg A, Rabin RL, Zhang HH, Gebeyehu S, Wright TM, Iwasaki A, Weng Y, DeMartino JA, Elkins KL, Farber JM (2002) The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol 169:1433-1443
60. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963-969
61. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM (1995) Human Mig chemokine: biochemical and functional characterization. J Exp Med 182:1301-1314
62. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289-295
63. Boccato S, Pistis R, Noventa F, Guido M, Benvegnù L, Alberti A (2006) Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 13:297-302
64. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, Pol S (2001) Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 32:904-909
65. Iredale JP (2003) Regulating hepatic inflammation: pathogen-associated molecular patterns take their toll. Hepatology 37:979-982
66. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR (2003) Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 74:360-369